Formerly President of the Advanced Therapies Division of Siemens Healthineers, he defined and led the development strategy of the interventional imaging business, focusing on oncology, neurology, and cardiovascular care, and was actively involved in the acquisition of Corindus and Varian for a total of nearly €18 billion. He also spent twelve years at Medtronic as Global Vice President & General Manager, in charge of the development and commercialization of innovative surgical devices.

Michel Therin will be responsible for implementing the commercialization strategy for Affluent Medical's devices, which address two unmet medical needs, cardiac mitral insufficiency and urinary incontinence in adults.

Kalios is the only prosthesis for mitral heart valve repair, which allows multiple postoperative readjustments via the transcatheter route without general anesthesia. The recently published intermediate clinical results of the pivotal study are very encouraging.

Epygon is the only physiological cardiac bioprosthesis that mimics the native mitral valve and blood flows, implanted by transcatheter, without “open heart” surgery. Patient screening is underway in several European countries for the first clinical trial in patients. Moderate to severe urinary incontinence is another major public health problem with more than 100 million adults worldwide currently affected by this pathology, which has no effective treatment and has a massive impact on patients' quality of life and psychological state. In total, the market for medical devices to treat urinary incontinence is expected to reach $4.3 billion in 2027, with an average annual growth rate of 11% between2019 and 2027.

Artus is the first artificial sphincter that can be activated by the patient via remote control to treat moderate to severe urinary incontinence in men and women. The pivotal clinical trial is planned for 2023.